TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26711719
Drug: M‐Ex‐M (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐Ex‐M (morning and evening metformin doses, with exercise)
Study: 26711719
Drug: M‐Ex (exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐Ex (exercise with evening metformin dose only)
Study: 26711719
Drug: Ex‐M (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex‐M (morning metformin dose only, with exercise)
Study: 26711719
Drug: M‐M (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐M (morning and evening metformin doses, without exercise)
Study: 15349656
Drug: rhEPO 6000IU
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 6000IU subcutaneously for 3 times a week and Ferrost sulfatis Et vitamini‐medtech 1 tablet per day for 12 days
Study: 15349656
Drug: Ferrost sulfatis
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrost sulfatis Et vitamini‐medtech (same dose as experimental group)
Study: 9028716
Drug: oral Etalpha
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Etalpha (0.25 microgram)
Study: 9028716
Drug: i.v. and
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. and oral 1,25‐dihydroxyvitamin D3
Study: 9028716
Drug: 1,25‐dihydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25‐dihydroxyvitamin D3 and insulin
Study: 27735028
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet with 500 mg of metformin twice a day (IM)
Study: 27735028
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet with 120 mg of orlistat three times a day (IO)
Study: 25474455
Drug: Cryosurgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryosurgery and 5-fluorouracil cream 0.5%
Study: 20512584
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - received 'today's treatment' without additional strength training.
Study: 8861991
Drug: Implantable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implantable insulin pump (IIP)
Study: 16120030
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin (MDI)
Study: 1735400
Drug: hyperbaric Niphanoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric Niphanoid tetracaine (6 or 10 mg)
Study: 1735400
Drug: hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric bupivacaine (6 mg)
Study: 1735400
Drug: hyperbaric Niphanoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric Niphanoid tetracaine (6 mg) with adrenaline
Study: 1735400
Drug: hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric bupivacaine (6 mg) with adrenaline
Study: 1735400
Drug: light intravenous
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: light intravenous supplementation with low doses of fentanyl and/or thiopentone
Study: 30732192
Drug: Furazolidone-based quadruple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based quadruple therapy (FZD) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Study: 30732192
Drug: Clarithromycin-based quadruple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based quadruple therapy (CLA) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Study: 24196279
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy (n = 41) and 76.2 Gy (n = 109) delivered in 32 and 33 fractions, respectively.
Study: 24196279
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy and 76.2 Gy.
Study: 19915736
Drug: Isoflavone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (100 mg/day for 4 months)
Study: 14639137
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (epsilon-ACA) prior to skin incision (bolus 150 mg/kg, followed by an infusion at 15 mg x kg(‐1) x hr(‐1))
Study: 14639137
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (epsilon-ACA) after heparin (same doses)
Study: 31377477
Drug: Lapatinib (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1500 mg/day)
Study: 31377477
Drug: Trastuzumab (common
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (common dose)
Study: 31377477
Drug: Lapatinib (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1000 mg/day) plus Trastuzumab
Study: 25581856
Drug: OND OSF
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OND OSF 8 mg (ZUPLENZ)
Study: 25581856
Drug: OND ODT
Normalized name: ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OND ODT 8 mg (ZOFRAN)
Study: 7805426
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily)
Study: 19833273
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (5 mg) with 2-minute sitting position after injection
Study: 19833273
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (5 mg) with 5-minute sitting position after injection
Study: 19833273
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (5 mg) with 10-minute sitting position after injection
Study: 8879466
Drug: 25‐mg CMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐mg CMI slow infusion
Study: 8879466
Drug: 25‐mg CMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐mg CMI tablet
Study: 31083777
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) therapy at 45 L/min
Study: 25349301
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI)
Study: 25349301
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 (GC)
Study: 25349301
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI) in second-/third-line treatment
Study: 22293533
Drug: PHX1766 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1766 800 mg twice daily
Study: 22293533
Drug: PHX1766 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1766 (various doses: 50 mg once daily - 1000 mg once daily, 250 mg twice daily)
Study: 2300922
Drug: Nonsteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid treatment
Study: 12739240
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment in cases with persistent canal paresis
Study: 12739240
Drug: Nonsteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid treatment in cases with persistent canal paresis
Study: 10595814
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) prophylaxis (500 mg/kg/d loading from day -6 to -1 and then 100 mg/kg every 3 days from day 3 to 90)
Study: 10595814
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) prophylaxis
Study: 29094998
Drug: Nutritional oral
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional oral formula (GS)
Study: 29094998
Drug: Nutritional oral
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional oral formula (GS) and Control (GC)
Study: 25946948
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% cream applied to the cervix
Study: 25946948
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the cervix
Study: 21906521
Drug: Tian Gui
Normalized name: Tian Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tian Gui Capsule
Study: 18710712
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days
Study: 17584010
Drug: 50-mg sildenafil
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg sildenafil
Study: 11275293
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration at 0700 h
Study: 7915672
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline and a breathing mixture of even parts of oxygen and nitrous oxide (Entonox)
Study: 7915672
Drug: Intravenous ketobemidone
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketobemidone hydrochloride 2.5 mg, midazolam 2.5 mg, and breathing air from a face mask with a demand valve (KHM)
Study: 31879235
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment plus standard of care (SOC)
Study: 31879235
Drug: Sham treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatments plus SOC
Study: 26693193
Drug: Conventional Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Exercise Therapy (CET)
Study: 23311458
Drug: Employee wellness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Employee wellness programme based on cognitive behaviour therapy (CBT) and weekly supervised exercise classes over six weeks.
Study: 16139813
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 8.7 +/- 7.1 mg/day)
Study: 12975627
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment protocol consisting of 4 different subprotocols
Study: 11076409
Drug: Osmo-adalat 30
Normalized name: nifedipine 30 MG [Adalat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmo-adalat 30 mg once daily for 3 weeks
Study: 11076409
Drug: Cordipin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordipin 10 mg three times a day
Study: 31036088
Drug: SIB radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SIB radiotherapy concurrent and consolidated with S-1
Study: 27179999
Drug: Ecopipam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (single large dose)
Study: 25033900
Drug: 20 G vitrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G vitrectomy
Study: 25033900
Drug: 23 G vitrectomy
Normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 G vitrectomy
Study: 25033900
Drug: Diabetic subgroup
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subgroup (20 G)
Study: 25033900
Drug: Diabetic subgroup
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subgroup (23 G)
Study: 25033900
Drug: Non-diabetic subgroup
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diabetic subgroup (20 G)
Study: 25033900
Drug: Non-diabetic subgroup
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diabetic subgroup (23 G)
Study: 22686944
Drug: Rivoglitazone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1.5 mg/day
Study: 22686944
Drug: Rivoglitazone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1.0 mg/day
Study: 22686944
Drug: Rivoglitazone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone (both doses)
Study: 18931238
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg preoperatively)
Study: 11956510
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg L‐796568
Study: 11956510
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg L‐796568
Study: 7618647
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at a dose of 0.7 pmol/kg/min for 3 hours
Study: 385095
Drug: Topical cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cephradine (1 g applied to the wound at closure)
Study: 385095
Drug: Systemic cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic cephradine (1 g intravenously at induction and 500 mg 4 h later)
Study: 29546579
Drug: Insulin or
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin or Dapagliflozin
Study: 23201768
Drug: 15.0 g
Normalized name: PYRITHIONE ZINC 15.0 g in 1.0 L TOPICAL SHAMPOO [Medaclear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.0 g egg white protein; 75 kcal
Study: 23201768
Drug: 17.5 g
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 g maltodextrin, 78 kcal
Study: 19960001
Drug: Alginate (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate (three capsules per day, ingested 30 min before the main meal)
Study: 19960001
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, three capsules per day, ingested 30 min before the main meal)
Study: 17408408
Drug: LY517717 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY517717 100 mg
Study: 17408408
Drug: LY517717 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY517717 125 mg
Study: 17408408
Drug: LY517717 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY517717 150 mg
Study: 17408408
Drug: LY517717 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY517717 (all doses)
Study: 12223253
Drug: CX516 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX516 (300 mg tid to 900 mg tid over 4 weeks)
Study: 8744964
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation at test
Study: 15764422
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluoxetine
Study: 6388247
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clomipramine
Study: 28697780
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of analgesia with steroid (LIA)
Study: 26032118
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (ropivacaine 0.5%, 20 ml on each side)
Study: 26032118
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block (isotonic saline 0.9%, 20 ml on each side)
Study: 22381601
Drug: Betamethasone 12-hour
Normalized name: betamethasone 0.12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 12-hour dosing interval
Study: 22381601
Drug: Betamethasone 24-hour
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 24-hour dosing interval
Study: 16222900
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and Ramipril 10 mg
Study: 8565983
Drug: Azithromycin (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (once daily for three days)
Study: 8565983
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (thrice daily for ten days)
Study: 2178656
Drug: Single heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single heparin bolus of 10,000 units (protocol I)
Study: 2178656
Drug: Heparin bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bolus of 10,000 units plus continuous infusion of 2000 units/hour (protocol II)
Study: 2178656
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion at the rate of 2000 units/hour for 24 hours post-angioplasty
Study: 23577619
Drug: Azithromycin and
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin and chloroquine fixed-dose combination (AZCQ)
Study: 19740297
Drug: Captopril (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.2 mg/kg/day) for 12 months
Study: 16782975
Drug: Propofol 3-5
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 3-5 mg kg(‐1) h(‐1)
Study: 10923605
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal azelastine (two sprays BID)
Study: 8833208
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg/day for 2 years followed by 5 mg/day for the 3rd year
Study: 3911964
Drug: Suprofen 300
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen 300 mg suppositories
Study: 20219110
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPV)
Study: 28679552
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (≥18 g NSP/d)
Study: 11349017
Drug: Placebo-vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-vaccine plus 25 microg of LT(R192G)
Study: 11349017
Drug: Placebo-vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-vaccine plus placebo-adjuvant
Study: 8997460
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (0.75 mg/kg) at gluteal site
Study: 8997460
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (0.75 mg/kg) at deltoid site
Study: 8997460
Drug: Both injection
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both injection sites (gluteal and deltoid)
Study: 7700051
Drug: Mild subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild subgroup (patients receiving conservative treatment of thrombectomy)
Study: 29664983
Drug: Ranibizumab (Lucentis;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (Lucentis; Genentech) monotherapy
Study: 29664983
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus peripheral laser (combination therapy)
Study: 26386793
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/d (5 mg/d for patients ≥75 years and/or <60 kg)
Study: 23130135
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d
Study: 17159259
Drug: He-Ne laser
Normalized name: Ne
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: He-Ne laser therapy (wavelength 632.8 nm, output 10mW)
Study: 17159259
Drug: Oral analgesics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics, local application of anaesthetics, 0.9% saline, and povidine wash
Study: 10862636
Drug: Isosorbide 5
Normalized name: Isosorbide 5-nitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide 5 mononitrate (40 mg)
Study: 9043272
Drug: J-pouch irrigations
Normalized name: hydroxypropyl cellulose (type J)
Approvals — FDA: no, EMA: no, PMDA: no
Description: J-pouch irrigations through the efferent ileostomy stoma, daily for 4 weeks.
Study: 1574953
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (400 micrograms iv)
Study: 2862223
Drug: Adjuvant oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oophorectomy followed by chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp)
Study: 2862223
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp) alone
Study: 2668051
Drug: Fructose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (50 g)
Study: 30529886
Drug: Sucralose (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (0.33 g)
Study: 30529886
Drug: Control (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (300 mL plain tap water)
Study: 27146650
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry (MC) juice (60 mL)
Study: 24963007
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator therapy (control)
Study: 20105186
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) 0.03 mg/kg per day
Study: 20105186
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) 0.06 mg/kg per day
Study: 15936184
Drug: Formoterol/budesonide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol/budesonide combination 9/320 microg
Study: 29162214
Drug: Rosuvastatin/ezetimibe fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/ezetimibe fixed-dose combination (FDC; 10 mg/10 mg)
Study: 29162214
Drug: Rosuvastatin/ezetimibe single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/ezetimibe single agents (10 mg/10 mg)
Study: 9094892
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (294 mg vitamin E, 1000 mg vitamin C, and 60 mg ubiquinone daily)